Activity of @entity2903 and bevacizumab in the treatment of locally advanced, recurrent, and metastatic XXXX and @entity2460 .

@entity1 @entity242 @entity2698 @entity5 @entity4306 @entity601 @entity74 @entity2903 @entity2460
BACKGROUND: @entity2698 and @entity2460 ( @entity4306 /SFT) are rare, closely related @entity242 with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced @entity4306 /SFT has not yet been identified. METHODS: We retrospectively analyzed the records of 14 @entity1 with histopathologically confirmed @entity4306 /SFT who were treated at The University of Texas @entity601 Anderson @entity5 Center between May 2005 and June 2007. All @entity1 were treated with @entity2903 150 mg/m(2) orally on days 1-7 and days 15-21 and bevacizumab 5 mg/kg intravenously on days 8 and 22, repeated at 28-day intervals. Computed tomography assessment of @entity5 size and density (Choi criteria) was used to determine the best response to therapy. The Kaplan-Meier method was used to estimate progression-free survival. RESULTS: The median follow-up period was 34 months. Eleven @entity1 (79%) achieved a Choi partial response, with a median time to response of 2.5 months. Two @entity1 (14%) had stable disease as the best response, and 1 @entity1 (7%) had @entity74 as the best response. The estimated median progression-free survival was 9.7 months, with a 6-month progression-free rate of 78.6%. The most frequently observed toxic effect was myelosuppression. CONCLUSION: Combination therapy with @entity2903 and bevacizumab is a generally well-tolerated and clinically beneficial regimen for @entity4306 /SFT @entity1 . Additional investigation in a controlled, prospective trial is warranted.
